Objectives: S. pneumoniae (SPN) continues to be recognized as a significant respiratory and bacteremic pathogen. Resistance to both oral and parenteral antibiotics used to treat SPN infection is evolving and newer antibiotics are needed with anti-SPN activity. This report documents the activity of tigecycline and comparators against 5501 SPN collected globally since 2004.
Objectives: S. pneumoniae (SPN) continues to be recognized as a significant respiratory and bacteremic pathogen. Resistance to both oral and parenteral antibiotics used to treat SPN infection is evolving and newer antibiotics are needed with anti-SPN activity. This report documents the activity of tigecycline and comparators against 5501 SPN collected globally since 2004.
Methods: Between 2004 Between -2007 hospital sites in 48 countries collected 5501 SPN deemed clinically significant from a variety of sources. MICs were determined at each site using supplied broth microdilution panels and MIC results interpreted by CLSI standards at each site.
Results: The % SPN inhibited at each MIC are shown below:
Conclusions: Tigecycline demonstrated excellent in vitro activity against SPN with 100% of isolates inhibited at ≤0.5 mcg/ml. Globally, only 61.5% of SPN were susceptible to penicillin, while 0.2% were resistant to levofloxacin. Background: Worldwide S. aureus are increasingly displaying resistance to multiple drug classes. Therapeutic options to multi-drug resistant (MDR) S. aureus phenotypes are limited. Tigecycline, a new glycylcycline offers the potential of enhanced activity against MDR S. aureus. The tigecycline evaluation surveillance trial (T.E.S.T.) evaluated the activity of tigecycline and comparators to MDR S. aureus isolated worldwide.
Methods: 335 hospital sites in 47 countries between 2004 and 2007 collected 7,557 clinically significant S. aureus. MICs were determined using broth microdilution panels and results interpreted as specified by CLSI at each site. S. aureus strains were categorized into groups according to the number of drug classes to which they were resistant (MDR groups 0 to 4).
Results: MIC 90 of tigecycline and comparators for MDR groups 0 to 4 are shown in the 
